Peter B. Cancelmo net worth and biography

Peter Cancelmo Biography and Net Worth

Vice President General Counsel and Secretary of Omeros

Peter B. Cancelmo, JD, has served as our vice president, general counsel and secretary since June 2019. He joined Omeros in January 2019 as deputy general counsel. Prior to joining Omeros, Mr Cancelmo was a principal and shareholder with Garvey Schubert Barer, P.C., where he represented clients in the life sciences and other technology industries in mergers, acquisitions, strategic alliances, public and private securities offerings, and a range of other corporate, commercial, and financial transactions. He served as chair of the firm’s business practice group from 2016 until his departure in December 2018. Before Garvey Schubert Barer, Mr Cancelmo practiced corporate and transactional law at Davies, Ward, Phillips and Vineberg LLP, in New York, and Choate, Hall & Stewart LLP, in Boston. Mr Cancelmo received his JD from Boston University and his BA from Saint Michael’s College.

What is Peter B. Cancelmo's net worth?: The estimated net worth of Peter B. Cancelmo is at least $3.89 thousand as of August 31st, 2026. Mr. Cancelmo owns 200 shares of Omeros stock worth more than $3,885 as of September 9th. This net worth estimate does not reflect any other assets that Mr. Cancelmo may own. Learn More about Peter B. Cancelmo's net worth.
How do I contact Peter B. Cancelmo?: The corporate mailing address for Mr. Cancelmo and other Omeros executives is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. Omeros can also be reached via phone at (206) 676-5000 and via email at [email protected]. Learn More on Peter B. Cancelmo's contact information.
Has Peter B. Cancelmo been buying or selling shares of Omeros?: Within the last three months, Peter B. Cancelmo has sold $929,750.00 of Omeros stock. Most recently, Peter B. Cancelmo sold 25,000 shares of the business's stock in a transaction on Monday, August 31st. The shares were sold at an average price of $18.54, for a transaction totalling $463,500.00. Following the completion of the sale, the vice president now directly owns 200 shares of the company's stock, valued at $3,708. Learn More on Peter B. Cancelmo's trading history.
Who are Omeros' active insiders?: Omeros' insider roster includes David Borges (CAO), Thomas Cable (Director), Peter Cancelmo (Vice President General Counsel and Secretary), Gregory Demopulos (CEO), Peter Demopulos (Director), Arnold Hanish (Director), and Michael Jacobsen (CAO). Learn More on Omeros' active insiders.
Are insiders buying or selling shares of Omeros?: During the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 133,406 shares worth more than $2,236,579.60. The most recent insider tranaction occured on August, 31st when VP Peter B. Cancelmo sold 25,000 shares worth more than $463,500.00. Insiders at Omeros own 10.5% of the company. Learn More about insider trades at Omeros.
Information on this page was last updated on 8/31/2026.

Peter B. Cancelmo Insider Trading History at Omeros

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/31/2026	Sell	25,000	$18.54	$463,500.00	200
8/28/2026	Sell	25,000	$18.65	$466,250.00	200

Peter B. Cancelmo Buying and Selling Activity at Omeros

Omeros Company Overview

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Today's Range

Now: $19.39

$18.93

$19.55

50 Day Range

MA: $13.89

$9.22

$19.32

2 Week Range

Now: $19.39

$3.94

$19.65

Volume

1,484,966 shs

Average Volume

1,693,492 shs

Market Capitalization

$1.40 billion

P/E Ratio

15.15

Dividend Yield

N/A

Beta

2.6